Loading
Life sciences · Phase 4 Trial
ClinicalTrials.gov · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 4 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05176626). This is a study registration, not published results. Lead sponsor: Wake Forest University Health Sciences. Recruitment status: COMPLETED. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 870 participants (ACTUAL). Conditions: Obesity, Obesity; Drug, Lifestyle, Healthy. Interventions: BEHAVIORAL: Online Lifestyle Behavioral Therapy; DRUG: Phentermine Hydrochloride 8 MG. Primary outcome measures: Change in body weight (%) , Baseline to month 24; Change in Systolic Blood Pressure (mmHg) , Baseline to month 24. Brief summary: The purpose of this research study is to understand the long-term effects of the drug phentermine on weight, blood pressure, other health outcomes, and safety. Phentermine has been approved by the US Food and Drug Administration (FDA) for weight management since 1959, but it has not been approved for long-term use (i.e., treatment lasting more than 12 weeks). This trial is designed to learn about the long-term effects of phentermine for up to 2 years because obesity is a chronic disease and expert guidelines recommend long-term use of anti-obesity medications as one treatment option.